Compare TLX & ICFI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TLX | ICFI |
|---|---|---|
| Founded | 2015 | 1969 |
| Country | Australia | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Professional Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 1.8B |
| IPO Year | N/A | 2006 |
| Metric | TLX | ICFI |
|---|---|---|
| Price | $10.75 | $70.31 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 4 |
| Target Price | $21.13 | ★ $99.25 |
| AVG Volume (30 Days) | 231.9K | ★ 270.9K |
| Earning Date | 08-19-2026 | 05-07-2026 |
| Dividend Yield | N/A | ★ 0.77% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 4.95 |
| Revenue | N/A | ★ $1,229,162,000.00 |
| Revenue This Year | N/A | $4.12 |
| Revenue Next Year | N/A | $5.33 |
| P/E Ratio | $150.33 | ★ $14.72 |
| Revenue Growth | N/A | ★ 3.72 |
| 52 Week Low | $6.28 | $64.34 |
| 52 Week High | $19.93 | $101.71 |
| Indicator | TLX | ICFI |
|---|---|---|
| Relative Strength Index (RSI) | 69.28 | 50.05 |
| Support Level | $10.60 | $64.34 |
| Resistance Level | $11.18 | $83.85 |
| Average True Range (ATR) | 0.33 | 2.28 |
| MACD | 0.08 | 1.04 |
| Stochastic Oscillator | 71.73 | 58.47 |
Telix develops radiopharmaceuticals to manage cancer. Radiopharmaceuticals are radioisotopes bound to molecules that can target specific cells. At low doses, these drugs can bind to specific cancer cells with radiation, and then positron emission tomography imaging can accurately visualize tumors. At high doses, these drugs can selectively target and treat tumors with radiation, known as radioligand therapy. Radiopharmaceuticals are usually injected into the bloodstream. Telix has a pipeline of potential radiopharmaceuticals but currently earns most of its revenue from US sales of Illuccix, largely used as an imaging agent to visualize the spread of prostate cancer.
ICF International Inc provides professional services and technology-based solutions to government and commercial clients, including management, marketing, technology, and policy consulting and implementation services. Its services support clients that operate in four key markets that include Energy, Environment, Infrastructure and Disaster Recovery; Health and Social Programs and Security and Other Civilian & Commercial. The Company's majority clients are United States federal government departments and agencies. It operates in a single segment, which is providing professional services.